# PRISMA 2020 Checklist

**Systematic Review Title:** Direct Endovascular Treatment Versus Bridging Therapy (Intravenous Thrombolysis Plus Endovascular Treatment) for Acute Large Vessel Occlusion Ischemic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

**Reference:** Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71.

---

| Section | Item # | Checklist Item | Reported on Page/Section |
|---|---|---|---|
| **TITLE** | 1 | Identify the report as a systematic review. | Title Page: title explicitly states "A Systematic Review and Meta-Analysis of Randomized Controlled Trials" |
| **ABSTRACT** | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | Abstract section: structured abstract with Background, Objective, Data Sources, Study Selection, Data Extraction and Quality Assessment, Data Synthesis and Results, Conclusions, and PROSPERO Registration |
| **INTRODUCTION** | | | |
| Rationale | 3 | Describe the rationale for the review in the context of existing knowledge. | Introduction, paragraphs 1-4: clinical burden of LVO stroke, evolution of reperfusion therapy, controversy regarding bridging vs. direct EVT, limitations of existing evidence |
| Objectives | 4 | Provide an explicit statement of the objective(s) or question(s) the review addresses. | Introduction, final paragraph: primary objective (non-inferiority of direct EVT for 90-day mRS 0-2) and secondary objectives (mortality, sICH, mTICI 2b-3, GRADE assessment) |
| **METHODS** | | | |
| Eligibility criteria | 5 | Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses. | Methods, Section 4.2 (Eligibility Criteria): detailed PICOS criteria with population, intervention, comparator, outcomes, and study design specifications |
| Information sources | 6 | Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted. | Methods, Section 4.3 (Information Sources and Search Strategy): PubMed/MEDLINE, Embase, CENTRAL, Web of Science, ClinicalTrials.gov, WHO ICTRP, reference lists, hand-searching; date range January 2000 to February 2026 |
| Search strategy | 7 | Present the full search strategies for all databases, registers and websites, including any filters and limits used. | Methods, Section 4.3; full PubMed strategy provided in Supplementary Materials (referenced in text) |
| Selection process | 8 | Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process. | Methods, Section 4.4 (Study Selection Process): two independent reviewers, conservative inclusion approach, disagreements resolved by consensus or third reviewer, Covidence software, Cohen's kappa |
| Data collection process | 9 | Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process. | Methods, Section 4.5 (Data Extraction): two independent reviewers, standardized pre-piloted extraction form, discrepancies resolved by discussion or adjudication |
| Data items | 10a | List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought, and if not, the methods used to decide which results to collect. | Methods, Section 4.2 (Outcomes subsection): primary outcome (90-day mRS 0-2), secondary outcomes (mortality, sICH, mTICI 2b-3) with definitions |
| | 10b | List and define all other variables for which data were sought. Describe any assumptions made about any missing or unclear information. | Methods, Section 4.5: study characteristics, participant characteristics, intervention details; back-calculation of event counts from percentages described |
| Study risk of bias assessment | 11 | Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process. | Methods, Section 4.6 (Risk of Bias Assessment): RoB 2 tool, five domains, two independent reviewers, disagreements resolved by discussion/adjudication, robvis R package for visualization |
| Effect measures | 12 | Specify for each outcome the effect measure(s) used in the synthesis or presentation of results. | Methods, Section 4.7 (Statistical Analysis - Effect measures): odds ratio (OR) with 95% CI for all binary outcomes; direction of effect explained |
| Synthesis methods | 13a | Describe the processes used to decide which studies were eligible for each synthesis. | Methods, Section 4.2 and 4.7: all included RCTs reporting relevant outcomes were eligible for synthesis |
| | 13b | Describe any methods required to prepare the data for presentation or synthesis, such as handling of multi-arm trials or missing summary statistics. | Methods, Section 4.5: back-calculation of event counts from percentages |
| | 13c | Describe any methods used to tabulate or visually display results of individual studies and syntheses. | Methods, Section 4.7: forest plots, funnel plots; Results sections: figures and tables referenced |
| | 13d | Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used. | Methods, Section 4.7: random-effects model (DL + HKSJ), heterogeneity assessment (Q, I-squared, tau-squared, prediction interval), R software (metafor, meta packages) |
| | 13e | Describe any methods used to explore possible causes of heterogeneity among study results. | Methods, Section 4.7 (Sensitivity analyses, Subgroup analyses): leave-one-out, model comparison, geographic region subgroup, chi-squared test for interaction |
| | 13f | Describe any sensitivity analyses conducted to assess robustness of the synthesized results. | Methods, Section 4.7 (Sensitivity analyses): leave-one-out, fixed-effect model, REML estimation, large trial restriction, SKIP exclusion |
| Reporting bias assessment | 14 | Describe any methods used to assess risk of bias due to missing results in a synthesis. | Methods, Section 4.7 (Publication bias): funnel plot, Egger's test, Begg's test, Duval-Tweedie trim-and-fill; acknowledgment of limited power with k=6 |
| Certainty assessment | 15 | Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome. | Methods, Section 4.8 (Certainty of Evidence): GRADE approach with five downgrading domains; initial high rating for RCTs |
| **RESULTS** | | | |
| Study selection | 16a | Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram. | Results, Section 5.1 (Study Selection): 685 records identified, 265 duplicates removed, 420 screened, 385 excluded at title/abstract, 35 sought for full-text, 34 assessed, 28 excluded, 6 included; Figure 1 referenced |
| | 16b | Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded. | Results, Section 5.1: exclusion reasons with counts (wrong design n=5, wrong population n=3, wrong intervention n=14, inaccessible data n=3, duplicate n=3); Supplementary Materials referenced |
| Study characteristics | 17 | Cite each included study and present its characteristics. | Results, Section 5.2 (Study Characteristics): all 6 RCTs cited with references 20-25; Table 1 and Table 2 |
| Risk of bias in studies | 18 | Present assessments of risk of bias for each included study. | Results, Section 5.3 (Risk of Bias): narrative summary with domain-level assessments; Figure 4 referenced |
| Results of individual studies | 19 | For all outcomes, present, for each study: (a) summary statistics for each group, and (b) an effect estimate and its precision. | Results, Section 5.4 (Primary Outcome) and 5.5 (Secondary Outcomes): individual study n/N, ORs, and 95% CIs reported in text and forest plots (Figures 2, 3) |
| Results of syntheses | 20a | For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies. | Results, Sections 5.2, 5.3: characteristics and RoB summarized before synthesis results |
| | 20b | Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect. | Results, Sections 5.4, 5.5: pooled ORs with 95% CIs, p-values, I-squared, tau-squared, prediction intervals for all four outcomes |
| | 20c | Present results of all investigations of possible causes of heterogeneity among study results. | Results, Section 5.8 (Subgroup Analysis): geographic region subgroup analysis with interaction test |
| | 20d | Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results. | Results, Section 5.6 (Sensitivity Analyses): leave-one-out, model comparison, large trial restriction, SKIP exclusion; eTable 1, eTable 2 |
| Reporting biases | 21 | Present assessments of risk of bias due to missing results in syntheses. | Results, Section 5.7 (Publication Bias): funnel plot (Figure 5), Egger's p=0.290, Begg's p=0.469, trim-and-fill k0=0; limitations of k<10 acknowledged |
| Certainty of evidence | 22 | Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed. | Results, Section 5.9 (GRADE Assessment) and Table 3: moderate for mRS 0-2 and mortality, low for sICH, high for mTICI 2b-3; reasons for downgrading specified |
| **DISCUSSION** | | | |
| Discussion | 23a | Provide a general interpretation of the results in the context of other evidence. | Discussion, Sections 6.1 (Summary of Main Findings) and 6.2 (Comparison with Previous Meta-Analyses) |
| | 23b | Discuss any limitations of the evidence included in the review. | Discussion, Section 6.6 (Limitations): open-label design, limited k, SKIP dosing, lack of IPD, anterior circulation predominance, tenecteplase data gap, 90-day follow-up only |
| | 23c | Discuss any limitations of the review processes used. | Discussion, Section 6.6: publication bias assessment limited by k<10, inability to conduct certain prespecified subgroup analyses due to lack of study-level stratified data |
| | 23d | Discuss implications of the results for practice, policy, and future research. | Discussion, Sections 6.3 (Clinical Implications) and 6.4 (Mechanistic Considerations); Conclusions section: future research priorities (IPD-MA, tenecteplase trials, posterior circulation studies) |
| **OTHER INFORMATION** | | | |
| Registration and protocol | 24a | Provide registration information for the review, including register name and registration number, or state that the review was not registered. | Abstract (PROSPERO Registration), Methods Section 4.1 (Protocol and Registration): PROSPERO CRD2026XXXXXXX |
| | 24b | Indicate where the review protocol can be accessed, or state that a protocol was not prepared. | Methods Section 4.1: protocol developed a priori following PRISMA-P 2015 guidelines; available upon request |
| | 24c | Describe and explain any amendments to information provided at registration or in the protocol. | Methods Section 4.1: any deviations documented in Supplementary Materials |
| Support | 25 | Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review. | Declarations section (Funding): to be completed |
| Competing interests | 26 | Declare any competing interests of review authors. | Declarations section (Conflicts of Interest): to be completed |
| Availability of data, code, and other materials | 27 | Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review. | Declarations section (Data Availability): extraction forms, R scripts, and summary datasets to be made available as supplementary materials upon publication |

---

*This checklist was completed in accordance with the PRISMA 2020 statement (Page et al., BMJ 2021;372:n71). All 27 items have been addressed and mapped to the corresponding manuscript sections.*
